Literature DB >> 25270739

Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.

Fei Guo1, Liu Feng, Ji-Long Hu, Mei-Ling Wang, Peng Luo, Xiao-Ming Zhong, An-Mei Deng.   

Abstract

Altered expression of prostate tumor overexpressed-1 (PTOV1) is observed in various types of human cancers. However, the role of PTOV1 in epithelial ovarian cancer (EOC) remains unclear. PTOV1 messenger (m)RNA expression in EOC patients was evaluated by quantitative real-time PCR (qRT-PCR). PTOV1 protein expression was also analyzed in archived paraffin-embedded EOC tissues using immunohistochemistry (IHC), and its association with overall survival of patients was analyzed by statistical analysis. Results from qRT-PCR analysis show that the expression level of PTOV1 mRNA was significantly higher in tumor tissues of EOC, compared to that in adjacent noncancerous tissues (P < 0.001). IHC staining showed that high expression of PTOV1 was detected in 57.2 % (87/152) of EOC cases. High expression of PTOV1 was significantly associated with pathological grade (P = 0.029) and clinical stage (P = 0.001). Moreover, the results of Kaplan-Meier analysis indicated that a high expression level of PTOV1 resulted in a significantly poor prognosis of EOC patients. Multivariate analysis showed that high expression of PTOV1 was an independent prognostic factor for overall survival (P < 0.001). In conclusion, PTOV1 protein abnormal expression might contribute to the malignant progression of EOC. High expression of PTOV1 predicts poor prognosis in patients with EOC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25270739     DOI: 10.1007/s13277-014-2662-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  15 in total

1.  Ovarian cancer risk associated with inherited inflammation-related variants.

Authors:  Kristin L White; Joellen M Schildkraut; Rachel T Palmieri; Edwin S Iversen; Andrew Berchuck; Robert A Vierkant; David N Rider; Bridget Charbonneau; Mine S Cicek; Rebecca Sutphen; Michael J Birrer; Paul P D Pharoah; Honglin Song; Jonathan Tyrer; Simon A Gayther; Susan J Ramus; Nicolas Wentzensen; Hannah P Yang; Montserrat Garcia-Closas; Catherine M Phelan; Julie M Cunningham; Brooke L Fridley; Thomas A Sellers; Ellen L Goode
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

2.  PTOV1 is overexpressed in human high-grade malignant tumors.

Authors:  Sara Fernández; Jose L Mosquera; Lide Alaña; Alex Sanchez-Pla; Juan Morote; Santiago Ramón Y Cajal; Jaume Reventós; Inés de Torres; Rosanna Paciucci
Journal:  Virchows Arch       Date:  2010-12-23       Impact factor: 4.064

3.  In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer.

Authors:  Takahiro Koyanagi; Yasuhiro Suzuki; Yasushi Saga; Shizuo Machida; Yuji Takei; Hiroyuki Fujiwara; Mitsuaki Suzuki; Yasufumi Sato
Journal:  Cancer Sci       Date:  2013-11-08       Impact factor: 6.716

4.  PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks.

Authors:  P Benedit; R Paciucci; T M Thomson; M Valeri; M Nadal; C Càceres; I de Torres; X Estivill; J J Lozano; J Morote; J Reventós
Journal:  Oncogene       Date:  2001-03-22       Impact factor: 9.867

5.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

6.  PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle.

Authors:  Anna Santamaría; Pedro L Fernández; Xavier Farré; Patricia Benedit; Jaume Reventós; Juan Morote; Rosanna Paciucci; Timothy M Thomson
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

7.  PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy.

Authors:  Juan Morote; Sara Fernández; Lide Alaña; Carmela Iglesias; Jacques Planas; Jaume Reventós; Santiago Ramón Y Cajal; Rosanna Paciucci; Inés M de Torres
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

Review 8.  Pharmacogenomics of taxane/platinum therapy in ovarian cancer.

Authors:  Sharon Marsh
Journal:  Int J Gynecol Cancer       Date:  2009-12       Impact factor: 3.437

Review 9.  Current status and evolution of preclinical drug development models of epithelial ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Ursula A Matulonis
Journal:  Front Oncol       Date:  2013-12-11       Impact factor: 6.244

10.  Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer.

Authors:  Fangyong Lei; Longjuan Zhang; Xinghua Li; Xi Lin; Shu Wu; Fengyan Li; Junling Liu
Journal:  BMC Cancer       Date:  2014-06-19       Impact factor: 4.430

View more
  6 in total

1.  SGK2, 14-3-3, and HUWE1 Cooperate to Control the Localization, Stability, and Function of the Oncoprotein PTOV1.

Authors:  Katie L Pennington; Colten M McEwan; James Woods; Colin M Muir; A G Pramoda Sahankumari; Riley Eastmond; Eranga R Balasooriya; Christina M Egbert; Sandeep Kaur; Tyler Heaton; Katherine K McCormack; Stephen R Piccolo; Manabu Kurokawa; Joshua L Andersen
Journal:  Mol Cancer Res       Date:  2021-10-15       Impact factor: 6.333

2.  Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.

Authors:  Steffen Rausch; Jörg Hennenlotter; Marcus Scharpf; Katharina Teepe; Ursula Kühs; Stefan Aufderklamm; Simone Bier; Johannes Mischinger; Georgios Gakis; Arnulf Stenzl; Christian Schwentner; Tilman Todenhöfer
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-08       Impact factor: 4.553

3.  hnRNPK-regulated PTOV1-AS1 modulates heme oxygenase-1 expression via miR-1207-5p.

Authors:  Chang Hoon Shin; Seongho Ryu; Hyeon Ho Kim
Journal:  BMB Rep       Date:  2017-04       Impact factor: 4.778

Review 4.  The role of prostate tumor overexpressed 1 in cancer progression.

Authors:  Verónica Cánovas; Matilde Lleonart; Juan Morote; Rosanna Paciucci
Journal:  Oncotarget       Date:  2017-02-14

5.  Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells.

Authors:  Verónica Cánovas; Yolanda Puñal; Valentina Maggio; Enric Redondo; Mercedes Marín; Begoña Mellado; Mireia Olivan; Matilde Lleonart; Jacques Planas; Juan Morote; Rosanna Paciucci
Journal:  Oncotarget       Date:  2017-07-22

6.  Prognostic significance of PTOV1 expression in cancers: A protocol for systematic review and meta-analysis.

Authors:  Yue Yang; Nan Li; Guangwei Tian
Journal:  Medicine (Baltimore)       Date:  2021-12-17       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.